About Balltec
Balltec was founded in 2004 in Morecambe, United Kingdom, within the pharmaceutical sector. System specialty pharmaceuticals and cephalosporin products are developed, produced, and distributed. Established brands cover cardiovascular treatments, anti-hepatitis B virus medications, anti-allergic drugs, and third-generation cephalosporin antibiotics. Research and development efforts are maintained, alongside quality controls throughout the product lifecycle.
- Headquarter Morecambe, United Kingdom
- Founders Robert Emmett
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Balltec Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Venterra Group
(Jun 17, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Balltec
Detailed funding history for Balltec
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Balltec
Balltec has secured backing from 1 investor. Prominent investors backing the company include Venterra Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of wind energy projects
|
Locked | Locked | Locked |
Investor details for Balltec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Balltec
Investment portfolio details for Balltec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Balltec
Detailed financials for Balltec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Balltec Comparisons
Peer comparison for Balltec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Balltec
Detailed competitors of Balltec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Balltec
Complete news archive for Balltec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Balltec
Balltec was founded in 2004.
Balltec is headquartered in Morecambe, United Kingdom.
Balltec was founded in 2004 in Morecambe, United Kingdom, within the pharmaceutical sector. System specialty pharmaceuticals and cephalosporin products are developed, produced, and distributed. Established brands cover cardiovascular treatments, anti-hepatitis B virus medications, anti-allergic drugs, and third-generation cephalosporin antibiotics. Research and development efforts are maintained, alongside quality controls throughout the product lifecycle.
Balltec has 1 investor. Key investors include Venterra Group.